Spelling suggestions: "subject:"squamous well carcinoma off lead anda neck"" "subject:"squamous well carcinoma off lead anda beck""
1 |
Biodegradable Polylactide-co-Glycolide-Chitosan Janus Nanoparticles for the Local Delivery of Multifaceted Drug Therapy for Oral Squamous Cell Carcinoma ChemopreventionBissonnette, Caroline January 2020 (has links)
No description available.
|
2 |
Methylation in head and neck squamous cell carcinomaBennett, Kristi Lynn. January 2007 (has links)
Thesis (Ph. D.)--Ohio State University, 2007. / Full text release at OhioLINK's ETD Center delayed at author's request
|
3 |
Vismodegib – Inhibitor des Hedgehog-Signaltransduktionsweges – in der ex-vivo-Chemoresponsetestung bei Kopf-Hals-TumorenLiebig, Hannes 28 September 2023 (has links)
Purpose: The Hedgehog-signalling pathway (Hh) is frequently active in head and neck squamous cell carcinoma (HNSCC). Overexpressed Hh associates with poor prognosis. The Hh inhibitor vismodegib targets smoothened (SMO) and, based on molecular data, may prevent resistance to EGFR targeting.
Methods: To elucidate potential roles of vismodegib in HNSCC therapy, its sole effects and those combined with cisplatin, docetaxel, and cetuximab on HNSCC cell lines were assessed by MTT metabolisation and BrdU incorporation. Colony formation (CF) of primary HNSCC cells was studied utilizing the FLAVINO-protocol. Combinatory effects were analysed regarding antagonism, additivity or synergism. Associations between the ex vivo detected mode of action of vismodegib with other treatments related to patient characteristics were assessed and progression-free survival (PFS) in patient groups compared using Kaplan-Meier curves.
Results: Vismodegib suppressed BrdU incorporation significantly stronger than MTT turnover; CF was significantly inhibited at ≥20 µM vismodegib while concentrations <20 µM acted hormetic. Combining 20 µM vismodegib plus docetaxel (T), cisplatin (P), and cetuximab (E), additively enhanced antitumoral activity in HNSCC samples from patients with superior PFS highlighting a potential role for ex-vivo testing of this combination for use as a prognostic classifier. Conclusion: We provide ex-vivo evidence for vismodegib’s potential in HNSCC therapies especially if combined with cetuximab, cisplatin and docetaxel.:Abkürzungsverzeichnis
1 Einleitung
1.1 Kopf-Hals-Tumore
1.1.1 Therapie von Kopf-Hals-TumoreN
1.1.2 Limitationen der etablierten Therapien
1.2 Eingesetzte Chemotherapeutika
1.2.1 Cisplatin
1.2.2 Docetaxel
1.2.3 Cetuximab
1.3 Hedgehog-Signaltransduktionsweg
1.3.1 Hedgehog-Signalweg und Karzinogenese
1.3.2 Vermittlung von Tumortherapieresistenz durch den Hedgehog-Signalweg
1.3.3 Zielgerichtete Tumortherapie durch Blockade des Hedgehog-Signalweges
1.4 Vismodegib
1.5 Ex-Vivo-Chemoresponse-Testung mittels FLAVINO-Assay
1.6 Zusammenfassung der Rationale der Untersuchung
1.7 Aufgabenstellung der Promotionsarbeit
2 Publikation
2.1 Reduzierte Proliferation und Koloniebildung von Plattenepithelkarzinomen der Kopf Hals Region unter dualer Inhibition des EGFR- und Hedgehog-Signalweges
3 Zusammenfassung der Arbeit
4 Literaturverzeichnis
5 Anlagen
5.1 Darstellung des Eigenanteils
5.2 Erklärung über die eigenständige Abfassung der Arbeit
5.3 Lebenslauf
5.4 Publikationen
5.5 Danksagung
|
4 |
Standardized Diagnostic Workup and Patient-Centered Decision Making for Surgery and Neck Dissection Followed by Risk-Factor Adapted Adjuvant Therapy Improve Loco-Regional Control in Local Advanced Oral Squamous Cell CarcinomaWichmann, Gunnar, Pavlychenko, Mykola, Willner, Maria, Halama, Dirk, Kuhnt, Thomas, Kluge, Regine, Gradistanac, Tanja, Fest, Sandra, Wald, Theresa, Lethaus, Bernd, Dietz, Andreas, Wiegand, Susanne, Zebralla, Veit 30 March 2023 (has links)
Background: Standardized staging procedures and presentation of oral squamous cell
carcinoma (OSCC) patients in multidisciplinary tumor boards (MDTB) before treatment
and utilization of elective neck dissection (ND) are expected to improve the outcome,
especially in local advanced LAOSCC (UICC stages III–IVB). As standardized diagnostics
but also increased heterogeneity in treatment applied so far have not been demonstrated
to improve outcome in LAOSCC, a retrospective study was initiated.
Methods: As MDTB was introduced into clinical routine in 2007, 316 LAOSCC patients
treated during 1991-2017 in our hospital were stratified into cohort 1 treated before
(n=104) and cohort 2 since 2007 (n=212). Clinical characteristics, diagnostic procedures
and treatment modality of patients were compared using Chi-square tests and outcome
analyzed applying Kaplan-Meier plots and log-rank tests as well as Cox proportional
hazard regression. Propensity scores (PS) were used to elucidate predictors for impaired
distant metastasis-free survival (DMFS) in PS-matched patients.
Results: Most patient characteristics and treatment modalities applied showed
insignificant alteration. Surgical treatment included significantly more often resection of
the primary tumor plus neck dissection, tracheostomy and percutaneous endoscopic
gastrostomy tube use. Cisplatin-based chemo-radiotherapy was the most frequent. Only
insignificant improved disease- (DFS), progression- (PFS) and event-free (EFS) as well as
tumor-specific (TSS) and overall survival (OS) were found after 2006 as local (LC) and locoregional
control (LRC) were significantly improved but DMFS significantly impaired.
Cox regression applied to PS-matched patients elucidated N3, belonging to cohort 2 and
cisplatin-based chemo-radiotherapy as independent predictors for shortened DMFS. The
along chemo-radiotherapy increased dexamethasone use in cohort 2 correlates with
increased DM.
Conclusions: Despite standardized diagnostic procedures, decision-making considering
clear indications and improved therapy algorithms leading to improved LC and LRC,
shortened DMFS hypothetically linked to increased dexamethasone use had a detrimental
effect on TSS and OS.
|
Page generated in 0.1037 seconds